T1	Participants 13 30	posterior uveitis
T2	Participants 229 261	noninfectious posterior uveitis.
T3	Participants 269 445	A 3-year, multicenter, randomized, historically controlled trial of the 0.59-mg FA intravitreous implant in 110 patients and the 2.1-mg FA intravitreous implant in 168 patients
T4	Participants 1364 1396	noninfectious posterior uveitis.
T5	Participants 1639 1671	noninfectious posterior uveitis.
